Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Research Abstract |
Cyclic phosphatidic acid (cPA) is a specific, high-affinity antagonist of PPARγ; however, the molecular mechanism by which cPA inhibits colon cancer proliferation remains to be clarified. Our report indicates that PPARγ is expressed at considerable levels in human colon cancer cell lines. cPA suppressed cell growth and induced DNA condensation through PPARγ inhibition. This report suggests that potential use of cPA in the development of drugs targeting colon cancer and possib ly other types of cancer.
|